PCI in the patient with in stent restenosis: Difference between revisions
Jump to navigation
Jump to search
(/* ACCF/AHA/SCAI 2011 Guideline Recommendations: Restenosis{{cite journal|author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, ...) |
No edit summary |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
'''''Synonyms and Keywords:''''' ISR | '''''Synonyms and Keywords:''''' ISR | ||
==Overview== | ==Overview== | ||
In-stent restenosis (ISR) is the most frequent late complication of [[stent]] implantation and occurs when there is a reoccurrence of [[stenosis]] in a [[lesion]] that was previously treated with a [[stent]]. In stent restenosis results from exaggerated neointimal formation. The lesion is primarily composed of [[smooth muscle cells]] and [[extracellular matrix]]. Intravascular ultrasound studies demonstrate that in stent restenosis is not due to extrinsic compression of the stent by scar tissue (i.e. there is not compression of the stent). | In-stent restenosis (ISR) is the most frequent late complication of [[stent]] implantation and occurs when there is a reoccurrence of [[stenosis]] in a [[lesion]] that was previously treated with a [[stent]]. In stent restenosis results from exaggerated neointimal formation. The lesion is primarily composed of [[smooth muscle cells]] and [[extracellular matrix]]. Intravascular ultrasound studies demonstrate that in stent restenosis is not due to extrinsic compression of the stent by scar tissue (i.e. there is not compression of the stent). | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Although ISR has traditionally occurred in 30-40% of treated [[lesions]], its incidence has been dramatically reduced by the development of [[drug-eluting stents]]. | Although ISR has traditionally occurred in 30-40% of treated [[lesions]], its incidence has been dramatically reduced by the development of [[drug-eluting stents]]. | ||
==Risk Factors== | ==Risk Factors== | ||
=== Patient-based Risk Factors=== | === Patient-based Risk Factors=== | ||
| Line 27: | Line 24: | ||
* A residual [[pressure gradient]] > 20 mmHg | * A residual [[pressure gradient]] > 20 mmHg | ||
* An increased number, overlap, and length of [[stents]] | * An increased number, overlap, and length of [[stents]] | ||
==Treatment== | |||
==2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions: Restenosis<ref name="pmid22070837">{{cite journal|author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions|journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24 |pages=2550–83|year=2011 |month=December|pmid=22070837 |doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref> | The major goal of treating in-stent restenosis is to minimize the chance of recurrent [[restenosis]]. If a bare metal stent develops ISR, then a drug eluting stent should be placed. If ISR develops in a drug eluting stent, there is no data to suggest that a different type of drug eluting stent will prevent a recurrence (e.g. switching from sirolimus to paclitaxel). While use of a cutting balloon may improve acute angiographic results, there is no data to suggests that the use of a cutting balloon reduces the risk of a recurrence. Radiation treatment or brachytherapy was used in the past to treat ISR, but this procedure was associated with a higher rate of late [[stent thrombosis]], and had fallen out of favor. | ||
==2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)<ref name="pmid22070837">{{cite journal|author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH |title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions|journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24|pages=2550–83|year=2011 |month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref>== | |||
===Restenosis (DO NOT EDIT)<ref name="pmid22070837">{{cite journal|author=Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH|title=2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions|journal=[[Journal of the American College of Cardiology]] |volume=58 |issue=24|pages=2550–83|year=2011|month=December|pmid=22070837|doi=10.1016/j.jacc.2011.08.006|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(11)02875-0|accessdate=2011-12-08|url=http://content.onlinejacc.org/cgi/reprint/58/24/2550.pdf|PDF}}</ref>=== | |||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Patients who develop clinical [[restenosis]] after [[balloon angioplasty]] should be treated with [[bare metal stent|bare metal stent (BMS)]] or [[drug eluting stent|drug eluting stent (DES)]] if anatomic factors are appropriate and if the patient is able to comply with and tolerate[[dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]].<ref name="pmid9834304">{{cite journal |author=Erbel R, Haude M, Höpp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P |title=Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group|journal=[[The New England Journal of Medicine]] |volume=339 |issue=23 |pages=1672–8 |year=1998|month=December |pmid=9834304 |doi=10.1056/NEJM199812033392304|url=http://dx.doi.org/10.1056/NEJM199812033392304 |accessdate=2011-12-16}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Patients who develop clinical [[restenosis]] after [[balloon angioplasty]] should be treated with [[bare metal stent|bare metal stent (BMS)]] or [[drug eluting stent|drug eluting stent (DES)]] if anatomic factors are appropriate and if the patient is able to comply with and tolerate [[dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]].<ref name="pmid9834304">{{cite journal |author=Erbel R, Haude M, Höpp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P|title=Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group|journal=[[The New England Journal of Medicine]] |volume=339 |issue=23 |pages=1672–8 |year=1998|month=December |pmid=9834304|doi=10.1056/NEJM199812033392304|url=http://dx.doi.org/10.1056/NEJM199812033392304 |accessdate=2011-12-16}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki> | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Patients who develop clinical [[restenosis]] after [[bare metal stent|bare metal stent (BMS)]] should be treated with [[drug eluting stent|drug eluting stent (DES)]] if anatomic factors are appropriate and the patient is able to comply with and tolerate [[dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]].<ref name="pmid16531619">{{cite journal |author=Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA|title=Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=295 |issue=11 |pages=1264–73 |year=2006 |month=March |pmid=16531619|doi=10.1001/jama.295.11.1264 |url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=16531619|accessdate=2011-12-16}}</ref><ref name="pmid17276188">{{cite journal |author=Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, Schömig A |title=Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials|journal=[[Journal of the American College of Cardiology]] |volume=49 |issue=5 |pages=616–23|year=2007 |month=February |pmid=17276188 |doi=10.1016/j.jacc.2006.10.049|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)02882-8|accessdate=2011-12-16}}</ref><ref name="pmid15644543">{{cite journal |author=Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A|title=Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial|journal=[[JAMA : the Journal of the American Medical Association]] |volume=293 |issue=2|pages=165–71 |year=2005 |month=January |pmid=15644543 |doi=10.1001/jama.293.2.165|url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15644543 |accessdate=2011-12-16}}</ref>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Patients who develop clinical [[restenosis]] after [[bare metal stent|bare metal stent (BMS)]] should be treated with [[drug eluting stent|drug eluting stent (DES)]] if anatomic factors are appropriate and the patient is able to comply with and tolerate [[dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]].<ref name="pmid16531619">{{cite journal |author=Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA|title=Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=295 |issue=11 |pages=1264–73 |year=2006 |month=March |pmid=16531619|doi=10.1001/jama.295.11.1264|url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=16531619|accessdate=2011-12-16}}</ref><ref name="pmid17276188">{{cite journal|author=Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, Schömig A |title=Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials|journal=[[Journal of the American College of Cardiology]]|volume=49 |issue=5 |pages=616–23|year=2007 |month=February |pmid=17276188|doi=10.1016/j.jacc.2006.10.049|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(06)02882-8|accessdate=2011-12-16}}</ref><ref name="pmid15644543">{{cite journal |author=Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A|title=Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial|journal=[[JAMA : the Journal of the American Medical Association]]|volume=293 |issue=2|pages=165–71 |year=2005 |month=January |pmid=15644543|doi=10.1001/jama.293.2.165|url=http://jama.ama-assn.org/cgi/pmidlookup?view=long&pmid=15644543 |accessdate=2011-12-16}}</ref>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])''<nowiki>"</nowiki> | ||
|} | |} | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
|colspan="1" style="text-align:center; background: | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | ||
|- | |- | ||
|bgcolor=" | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[IVUS]] is reasonable to determine the mechanism of [[restenosis|stent restenosis]].<ref name="pmid21109112">{{cite journal |author=Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R |title=In-stent restenosis in the drug-eluting stent era |journal=[[Journal of the American College of Cardiology]] |volume=56 |issue=23 |pages=1897–907 |year=2010|month=November|pmid=21109112|doi=10.1016/j.jacc.2010.07.028|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)03986-0|accessdate=2011-12-16}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class | | colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]] | ||
|- | |- | ||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' [[ | |bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' Patients who develop clinical [[restenosis]] after [[drug eluting stent|drug eluting stent (DES)]] may be considered for repeat PCI with [[balloon angioplasty]], [[bare metal stent|bare metal stent (BMS)]], or [[drug eluting stent|drug eluting stent (DES)]] containing the same drug or an alternative antiproliferative drug if anatomic factors are appropriate and the patient is able to comply with and tolerate [[dual antiplatelet therapy|dual antiplatelet therapy (DAPT)]].<ref name="pmid21109112">{{cite journal |author=Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R |title=In-stent restenosis in the drug-eluting stent era|journal=[[Journal of the American College of Cardiology]] |volume=56 |issue=23 |pages=1897–907 |year=2010 |month=November|pmid=21109112|doi=10.1016/j.jacc.2010.07.028|url=http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(10)03986-0|accessdate=2011-12-16}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])''<nowiki>"</nowiki> | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 13:52, 6 November 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Laura Nasrallah, M.D.;
Synonyms and Keywords: ISR
Overview
In-stent restenosis (ISR) is the most frequent late complication of stent implantation and occurs when there is a reoccurrence of stenosis in a lesion that was previously treated with a stent. In stent restenosis results from exaggerated neointimal formation. The lesion is primarily composed of smooth muscle cells and extracellular matrix. Intravascular ultrasound studies demonstrate that in stent restenosis is not due to extrinsic compression of the stent by scar tissue (i.e. there is not compression of the stent).
Epidemiology and Demographics
Although ISR has traditionally occurred in 30-40% of treated lesions, its incidence has been dramatically reduced by the development of drug-eluting stents.
Risk Factors
Patient-based Risk Factors
Lesion-based Risk Factors
- Longer lesion length
- Smaller caliber vessel
- Greater plaque burden
- Ostial lesion location
- The presence of a chronic total occlusion
- Left anterior descending coronary artery location
- Saphenous vein graft lesion
Procedure Based Risk Factors
- A residual stenosis >30%
- A residual pressure gradient > 20 mmHg
- An increased number, overlap, and length of stents
Treatment
The major goal of treating in-stent restenosis is to minimize the chance of recurrent restenosis. If a bare metal stent develops ISR, then a drug eluting stent should be placed. If ISR develops in a drug eluting stent, there is no data to suggest that a different type of drug eluting stent will prevent a recurrence (e.g. switching from sirolimus to paclitaxel). While use of a cutting balloon may improve acute angiographic results, there is no data to suggests that the use of a cutting balloon reduces the risk of a recurrence. Radiation treatment or brachytherapy was used in the past to treat ISR, but this procedure was associated with a higher rate of late stent thrombosis, and had fallen out of favor.
2011 ACCF/AHA/SCAI Guidelines for Percutaneous Coronary Intervention (DO NOT EDIT)[1]
Restenosis (DO NOT EDIT)[1]
| Class I |
| "1. Patients who develop clinical restenosis after balloon angioplasty should be treated with bare metal stent (BMS) or drug eluting stent (DES) if anatomic factors are appropriate and if the patient is able to comply with and tolerate dual antiplatelet therapy (DAPT).[2] (Level of Evidence: B)" |
| "2. Patients who develop clinical restenosis after bare metal stent (BMS) should be treated with drug eluting stent (DES) if anatomic factors are appropriate and the patient is able to comply with and tolerate dual antiplatelet therapy (DAPT).[3][4][5](Level of Evidence: A)" |
| Class IIa |
| "1. IVUS is reasonable to determine the mechanism of stent restenosis.[6] (Level of Evidence: C)" |
| Class IIb |
| "1. Patients who develop clinical restenosis after drug eluting stent (DES) may be considered for repeat PCI with balloon angioplasty, bare metal stent (BMS), or drug eluting stent (DES) containing the same drug or an alternative antiproliferative drug if anatomic factors are appropriate and the patient is able to comply with and tolerate dual antiplatelet therapy (DAPT).[6] (Level of Evidence: C)" |
References
- ↑ 1.0 1.1 Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH (2011). "2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions" (PDF). Journal of the American College of Cardiology. 58 (24): 2550–83. doi:10.1016/j.jacc.2011.08.006. PMID 22070837. Retrieved 2011-12-08. Text "PDF" ignored (help); Unknown parameter
|month=ignored (help) - ↑ Erbel R, Haude M, Höpp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst P (1998). "Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group". The New England Journal of Medicine. 339 (23): 1672–8. doi:10.1056/NEJM199812033392304. PMID 9834304. Retrieved 2011-12-16. Unknown parameter
|month=ignored (help) - ↑ Holmes DR, Teirstein P, Satler L, Sketch M, O'Malley J, Popma JJ, Kuntz RE, Fitzgerald PJ, Wang H, Caramanica E, Cohen SA (2006). "Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial". JAMA : the Journal of the American Medical Association. 295 (11): 1264–73. doi:10.1001/jama.295.11.1264. PMID 16531619. Retrieved 2011-12-16. Unknown parameter
|month=ignored (help) - ↑ Dibra A, Kastrati A, Alfonso F, Seyfarth M, Pérez-Vizcayno MJ, Mehilli J, Schömig A (2007). "Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials". Journal of the American College of Cardiology. 49 (5): 616–23. doi:10.1016/j.jacc.2006.10.049. PMID 17276188. Retrieved 2011-12-16. Unknown parameter
|month=ignored (help) - ↑ Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schühlen H, Schmitt C, Dirschinger J, Schömig A (2005). "Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial". JAMA : the Journal of the American Medical Association. 293 (2): 165–71. doi:10.1001/jama.293.2.165. PMID 15644543. Retrieved 2011-12-16. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R (2010). "In-stent restenosis in the drug-eluting stent era". Journal of the American College of Cardiology. 56 (23): 1897–907. doi:10.1016/j.jacc.2010.07.028. PMID 21109112. Retrieved 2011-12-16. Unknown parameter
|month=ignored (help)